Showing results (1711-1720 of 5,607) with videos related to

Sort By:
Pageof 561
Nuclear Medicine Communications|March 16, 2011
Characterization of thymic lesions with F-18 FDG PET-CT: an emphasis on epithelial tumorsYiyan Liu
Nuclear Medicine Communications|March 18, 2011
18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastasesMaurice Henry Zissen, Pamela Kunz, Murugesan Subbarayan, et al.
Nuclear Medicine Communications|March 12, 2011
Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancerPaolo Castellucci, Chiara Fuccio, Maria Cristina Marzola, et al.
Nuclear Medicine Communications|August 1, 1997
The development of regional nuclear medicine audit in south ThamesF Forbes, S E Clarke, M Buxton-Thomas, et al.
Nuclear Medicine Communications|March 3, 1998
2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration?T Müller, E G Eising, C Reiners, et al.
Nuclear Medicine Communications|March 3, 1998
Cardiac axis change between prone and supine positioning may contribute to differences in 99Tc(m)-MIBI myocardial SPET imagingC Jeanguillaume, J Bochet, F Chehade, et al.
Nuclear Medicine Communications|April 19, 2015
Quantification of metabolic tumor activity and burden in patients with non-small-cell lung cancer: Is manual adjustment of semiautomatic gradient-based measurements necessary?Piotr Obara, Haiping Liu, Kristen Wroblewski, et al.
Nuclear Medicine Communications|May 9, 2015
Is choline PET useful for identifying intraprostatic tumour lesions? A literature reviewJoachim Chan, Isabel Syndikus, Shelan Mahmood, et al.
Nuclear Medicine Communications|May 15, 2020
18F-choline PET/computed tomography and clinical parameters in the detection of significant prostate cancer in patients with increased prostate-specific antigen levels and previous negative biopsiesGermán Andrés Jiménez Londoño, Ana Maria García Vicente, Edel Noriega Álvarez, et al.
Nuclear Medicine Communications|May 15, 2020
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic reviewCati Raluca Stolniceanu, Ionut Nistor, Stefana Catalina Bilha, et al.
Pageof 561